|
|
| Maladies Infectieuses > Etude de marché sectorielle |
| Disease and Therapy Review: Hepatitis C |
|
|
|
|
€ 720,00 |
Editeur
: |
Timely Data Resources |
Langue
: |
Anglais |
Date de publication : |
Janvier 2007 |
Taille du document : |
7 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Tropical and Defense Vaccines - The Scared, the Weak and the Poor
99 pages | Mai 2005 |
IntroductionTropical diseases account for around 5 million deaths per year (WHO, 2002).
Major contributors to these numbers are the mosquito borne diseases, which include West Nile Fever, Japanese |
1 520,00 €
|
| |
| |
Monoclonal Antibody Therapies: Sector Analysis Tool
pages | Avril 2005 |
IntroductionThe mAb Sector Analysis Tool presents the marketed and R&D portfolios, technology focus and product development strategies of over 100 key players in the mAbs market.
In addition, you c |
6 080,00 €
|
| |
| |
Antiviral HIV Treatment in Developing Countries Number of Patients
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
The Vaccines Market Outlook: Market analysis of future growth and leading players by sector
122 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Vaccines Market Outlook: Market analysis of future growth and leading players by sector.’ This unique report provides unrivalled ana |
2 443,75 €
|
| |
| |
Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu
166 pages | Décembre 2005 |
IntroductionInfluenza is a highly infectious disease which globally infects 10-20% of the population every year causing up to 500,000 deaths.
Although all persons are at risk, the elderly and the y |
6 460,00 €
|
| |
| |
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
329 pages | Décembre 2004 |
IntroductionAccording to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV.
Although HBV vaccination and routine screening of donated blood has decreased inciden |
12 160,00 €
|
| |
| |
Stakeholder Insight: HIV - A way of life
284 pages | Octobre 2005 |
IntroductionHIV is now considered a chronic, manageable disease.
However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are be |
12 920,00 €
|
| |
| |
Pipeline Insight: Hematological malignancies - Targeted treatments and immunotherapy infuse new blood
219 pages | Avril 2005 |
IntroductionGiven an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche's Rituxan, it is no surprise that targeted treat |
9 120,00 €
|
| |
| |
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
329 pages | Décembre 2004 |
IntroductionAccording to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV.
Although HBV vaccination and routine screening of donated blood has decreased inciden |
12 160,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Disease and Therapy Review: Hepatitis C |
|
|
The Hepatitis C Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments. Dosing information and treatment costs are provided for Peg-Intron, Pegasys, Rebetol, Copegus, and generic ribavirin capsules. General information on sales of peginterferon and ribavirin is provided.
Additional Information
Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
|
|
I. Overview
II. Incidence and Prevalence
Incidence Table: (US, Canada, UK)
Prevalence Table: (US, UK, France, Germany, Italy, Spain, Japan, China, India, Mexico, Worldwide)
III. Treatment
IV. Dosing
Peginterferon
Ribavirin
V. TREATMENT COSTS
VI. Market Size
VII. COMMENTS
VIII. References/Resources
|
|
|
PPLSEN
|
|
|
|
|
